
DexCom (DXCM) Stock Forecast & Price Target
DexCom (DXCM) Analyst Ratings
Bulls say
DexCom is a global leader in the growing market of continuous glucose monitoring, with its innovative CGM devices and software facilitating better management for diabetic patients. The company boasts strong revenue growth and profitability, driven by its expanding presence in the US and OUS markets, as well as its pipeline of product enhancements. With a solid balance sheet and ongoing investments in R&D and acquisitions, DexCom is well positioned for continued success and remains a Buy.
Bears say
DexCom is facing potential challenges with incremental commercial and Medicare coverage expansion in the future, as well as concerns about its revenue seasonality and pharmacy mix going forward. It is also facing potential pressure on expenses due to the operation of a new facility in Ireland. Additionally, while the company shows promise in the growing OUS market, there are execution risks and potential for continuing to trade at a discount to peers. The recent revenue report was in line with expectations and the company continues to iterate its offerings, but there may be challenges in maintaining its status while dealing with FDA decisions and coverage for non-insulin Type 2 patients. Though the company has an upcoming RCT and investor day, the current PT reflects a discounted value in comparison to similar companies.
This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.
DexCom (DXCM) Analyst Forecast & Price Prediction
Start investing in DexCom (DXCM)
Order type
Buy in
Order amount
Est. shares
0 shares